• Abdelmalek M, Ludwig J, Lindor KD 1995 Two cases from the spectrum of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 20: 127-130.

• Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD 2001 Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am. J. Gastroenterol. 96: 2711-2717. *

• Abrams GA, Kunde SS, Lazenby AJ, Clements RH 2004 Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 40: 475-483. *

• Adams LA, Feldstein A, Lindor KD, Angulo P 2004 Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 39: 909-914. *

• Adams LA, Zein CO, Angulo P, Lindor KD 2004 A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99: 2365-2368. *

• Agarwal N, Sharma BC 2005 Insulin resistance and clinical aspects of non-alcoholic steatohepatitis (NASH). Hepatol. Res. 33: 92-96.

• Ahima RS 2007 Insulin resistance: cause or consequence of nonalcoholic steatohepatitis? Gastroenterology 132: 444-446. *

• Ahmed MH 2006 Invasive and non-invasive investigations for non-alcoholic steatohepatitis (NASH): the need for biochemical markers. Scand. J. Gastroenterol. 41: 372. *

• Aithal GP 2007 Dangerous liaisons: drug, host and the environment. J. Hepatol. 46: 995-998. *

• Akin K, Beyler AR, Kaya M, Erden E 2003 The importance of iron and copper accumulation in the pathogenesis of non-alcoholic steatohepatitis. Turk. J. Gastroenterol. 14: 228-233. *

• Alazmi W, Bustamante M, O'loughlin C, Gonzalez J, Raskin JB 2006 The association of Streptococcus bovis bacteremia and gastrointestinal diseases: a retrospective analysis. Dig. Dis. Sci. 51: 732-736. *

• Alba LM, Lindor K 2003 Review article: non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 17: 977-986. *

• Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD, Day CP 2005 Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 54: 987-993. *

• Allard JP, Aghdassi E, Mohammed S, Raman M, Avand G, Arendt BM, Jalali P, Kandasamy T, Prayitno N, Sherman M, Guindi M, Ma DW, Heathcote JE 2008 Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J. Hepatol. 48: 300-307.

• Amarapurka DN, Amarapurkar AD, Patel ND, Agal S, Baigal R, Gupte P, Pramanik S 2006 Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Ann. Hepatol. 5: 30-33. *

• Amarapurkar A, Ghansar T 2007 Fatty liver: experience from western India. Ann. Hepatol. 6: 37-40. *

• Amarapurkar DN, Patel ND 2004 Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values. Trop. Gastroenterol. 25: 130-134.

• Amarapurkar DN, Patel ND, Kamani PM 2008 Impact of diabetes mellitus on outcome of HCC. Ann. Hepatol. 7: 148-151. *

• Angulo P 2003 Non-alcoholic steatohepatitis. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 87-88. October 17 - 19. *

• Angulo P 2002 Treatment of nonalcoholic fatty liver disease. Ann. Hepatol. 1: 12-19. *

• Angulo P 2002 Use of ursodeoxycholic acid in patients with liver disease. Curr. Gastroenterol. Rep. 4: 37-44.

• Angulo P, Keach JC, Batts KP, Lindor KD 1999 Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30: 1356-1362. *

• Angulo P, Lindor KD 2002 Non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 17 Suppl.: 186S-190S. *

• Angulo P, Lindor KD 2002 Treatment of non-alcoholic steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 16: 797-810. *

• Argo CK, Loria P, Caldwell SH, Lonardo A 2008 Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 48: 662-669.

• Arundel C, Lewis JH 2007 Drug-induced liver disease in 2006. Curr. Opin. Gastroenterol. 23: 244-254.

• Bahcecioglu IH, Yalniz M, Ataseven H, Ilhan N, Ozercan IH, Seckin D, Sahin K 2005 Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology 52: 1549-1553.

• Bahrami H, Daryani NE, Mirmomen S, Kamangar F, Haghpanah B, Djalili M 2003 Clinical and histological features of nonalcoholic steatohepatitis in Iranian patients. BMC Gastroenterol. 3: 27. *

• Balaban YH, Korkusuz P, Simsek H, Gokcan H, Gedikoglu G, Pinar A, Hascelik G, Asan E, Hamaloglu E, Tatar G 2007 Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann. Hepatol. 6: 242-250. *

• Balaban YH, Sumer H, Simsek H, Us D, Tatar G 2006 Metabolic syndrome, non-alcoholic steatohepatitis (NASH), and hepatocyte growth factor (HGF). Ann. Hepatol. 5: 109-114. *

• Baranova A, Liotta L, Petricoin E, Younossi ZM 2007 The role of genomics and proteomics: technologies in studying non-alcoholic fatty liver disease. Clin. Liver Dis.11: 209-220.

• Barbuio R, Milanski M, Bertolo MB, Saad MJ, Velloso LA 2007 Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J. Endocrinol. 194: 539-550. *

• Bardella MT, Valenti L, Pagliari C, Peracchi M, Fare M, Fracanzani AL, Fargion S 2004 Searching for coeliac disease in patients with non-alcoholic fatty liver disease. Dig. Liver Dis. 36: 333-336.

• Beath SV 2003 Hepatic function and physiology in the newborn. Semin. Neonatol. 8: 337-346.

• Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K 2006 A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355: 2297-2307. *

• Bell DS, Allbright E 2007 The multifaceted associations of hepatobiliary disease and diabetes. Endocr. Pract. 13: 300-312.

• Beraza N, Malato Y, Vander Borght S, Liedtke C, Wasmuth HE, Dreano M, de Vos R, Roskams T, Trautwein C 2008 Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. Gut 57: 655-663.

• Berg T, Neuhaus R, Klein R, Leder K, Lobeck H, Bechstein WO, Muller AR, Wiedenmann B, Hopf U, Berg PA, Neuhaus P 2002 Distinct enzyme profiles in patients with cryptogenic cirrhosis reflect heterogeneous causes with different outcomes after liver transplantation (OLT): a long-term documentation before and after OLT. Transplantation 74: 792-798.

• Bernal-Reyes R, Escudero RB 2002 Treatment of non-alcoholic steatohepatitis (NASH). A comparative study of ursodeoxycholic acid and alpha-tocopherol. A preliminary report. Rev. Gastroenterol. Mex. 67: 70-75.

• Bhattacharya R, Kowdley KV 2003 Iron and HFE mutations in nonalcoholic steatohepatitis: innocent bystanders or accessories to the crime? Gastroenterology 125: 615-616. *

• Blackburn GL, Mun EC 2004 Effects of weight loss surgeries on liver disease. Semin. Liver Dis. 24: 371-379.

• Boctor FN, Gorak E, Prichard JW, Firouzi M, Difilippo W 2008 Unusual warm autoimmune hemolytic anemia in non-alcoholic steatohepatitis. Ann. Clin. Lab. Sci. 38: 273-276.

• Bondini S, Kleiner DE, Goodman ZD, Gramlich T, Younossi ZM 2007 Pathologic assessment of non-alcoholic fatty liver disease. Clin. Liver Dis.11: 17-23.

• Bonkovsky HL, Lambrecht RW 2000 Iron-induced liver injury. Clin. Liver Dis. 4: 409-429, vi-vii.

• Bookman ID, Pham J, Guindi M, Heathcote EJ 2006 Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins. Liver Int. 26: 566-571. *

• Browning JD, Kumar KS, Saboorian MH, Thiele DL 2004 Ethnic differences in the prevalence of cryptogenic cirrhosis. Am. J. Gastroenterol. 99: 292-298. *

• Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palu' G, Martines D 2007 Increased intestinal permeability in obese mice: new evidences in the pathogenesis of nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G518-G525. *

• Brun P, Castagliuolo I, Floreani AR, Buda A, Blasone L, Palu G, Martines D 2006 Increased risk of NASH in patients carrying the C(-159)T polymorphism in the CD14 gene promoter region. Gut 55: 1212. *

• Brunt EM 2001 Nonalcoholic steatohepatitis: definition and pathology. Semin. Liver Dis. 21: 3-16.

• Brunt EM 2004 Nonalcoholic steatohepatitis. Semin. Liver Dis. 24: 3-20.

• Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR 1999 Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94: 2467-2474. *

• Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR 2004 Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum. Pathol. 35: 1070-1082.

• Brunt EM, Ramrakhiani S, Cordes BG, Neuschwander-Tetri BA, Janney CG, Bacon BR, Di Bisceglie AM 2003 Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod. Pathol. 16: 49-56. *

• Brunt EM, Tiniakos DG 2005 Pathological features of NASH. Front. Biosci. 10: 1475-1484.

• Brunt EM, Wolverson MK, Di Bisceglie AM 2005 Benign hepatocellular tumors (adenomatosis) in nonalcoholic steatohepatitis: a case report. Semin. Liver Dis. 25: 230-236.

• Buckingham RE 2005 Thiazolidinediones: pleiotropic drugs with potent anti-inflammatory properties for tissue protection. Hepatol. Res. 33: 167-170.

• Bugianesi E 2005 Late complications of NASH: a challenge for hepatologists. J. Hepatol. 42: 784-785.

• Bugianesi E 2007 Non-alcoholic steatohepatitis and cancer. Clin. Liver Dis.11: 191-207.

• Bugianesi E, Bellentani S, Bedogni G, Tiribelli C; Fatty Liver Italian Network 2008 Clinical update on non-alcoholic fatty liver disease and steatohepatitis. Ann. Hepatol. 7: 157-160. *

• Bugianesi E, Marzocchi R, Villanova N, Marchesini G 2004 Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Best Pract. Res. Clin. Gastroenterol. 18: 1105-1116.

• Bullock RE, Zaitoun AM, Aithal GP, Ryder SD, Beckingham IJ, Lobo DN 2004 Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. J. Hepatol. 41: 685-686. *

• Burke A, Lucey MR 2004 Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am. J. Transplant. 4: 686-693. *

• Byron D, Minuk GY 1996 Clinical hepatology: profile of an urban, hospital-based practice. Hepatology 24: 813-815. *

• Caldwell SH, Argo CK, Al-Osaimi AM 2006 Therapy of NAFLD: insulin sensitizing agents. J. Clin. Gastroenterol. 40 Suppl. 1: S61-S66.

• Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM 2004 Obesity and hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S97-S103. *

• Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL 2001 A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 96: 519-525. *

• Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ 1999 Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29: 664-669. *

• Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, Tiwari U, Ferrel L, Pabst M, Bass NM, Merriman RB 2008 A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 47: 1916-1923.

• Canbakan B, Tahan V, Balci H, Hatemi I, Erer B, Ozbay G, Sut N, Hacibekiroglu M, Imeryuz N, Senturk H 2008 Leptin in nonalcoholic fatty liver disease. Ann. Hepatol. 7: 249-254. *

• Canbay A, Bechmann LP, Best J, Jochum C, Treichel U, Gerken G 2006 Crohn's disease-induced non-alcoholic fatty liver disease (NAFLD) sensitizes for severe acute hepatitis B infection and liver failure. Z. Gastroenterol. 44: 245-248.

• Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Barve S, Barve S, McClain C 2007 Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J. Nutr. Biochem. 18: 184-195. *

• Cayon A, Crespo J, Guerra AR, Pons-Romero F 2008 Gene expression in obese patients with non-alcoholic steatohepatitis. Rev. Esp. Enferm. Dig. 100: 212-218.

• Chalasani N, Deeg MA, Crabb DW 2004 Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99: 1497-1502. *

• Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, Crabb DW 2003 Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 37: 544-550. *

• Chalasani N, Teal E, Hall SD 2005 Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am. J. Gastroenterol. 100: 1317-1321. *

• Chang CY, Argo CK, Al-Osaimi AM, Caldwell SH 2006 Therapy of NAFLD: antioxidants and cytoprotective agents. J. Clin. Gastroenterol. 40 Suppl. 1: S51-S60.

• Chapman RW 2003 To perform or not to perform liver biopsy: an alternative view. Gut 52: 1227. *

• Charatcharoenwitthaya P, Levy C, Angulo P, Keach J, Jorgensen R, Lindor KD 2007 Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. Liver Int. 27: 220-226. *

• Charatcharoenwitthaya P, Lindor KD 2007 Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin. Liver Dis.11: 37-54.

• Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, Rosen CB, Batts KP 2001 Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl. 7: 608-614. *

• Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS 2002 Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 35: 898-904. *

• Chitturi S, Farrell GC 2001 Etiopathogenesis of nonalcoholic steatohepatitis. Semin. Liver Dis. 21: 27-41.

• Choi S, Diehl AM 2005 Role of inflammation in nonalcoholic steatohepatitis. Curr. Opin. Gastroenterol. 21: 702-707.

• Choudhury J, Sanyal AJ 2005 Insulin resistance in NASH. Front. Biosci. 10: 1520-1533.

• Cindoruk M, Cirak MY, Unal S, Karakan T, Erkan G, Engin D, Dumlu S, Turet S 2008 Identification of Helicobacter species by 16S rDNA PCR and sequence analysis in human liver samples from patients with various etiologies of benign liver diseases. Eur. J. Gastroenterol. Hepatol. 20: 33-36.

• Clarke SD 2001 Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. Am. J. Physiol. Gastrointest. Liver Physiol. 281: G865-G869. *

• Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, Fisher RA, Ham J, Sanyal AJ 2001 Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 7: 363-373. *

• Cortez-Pinto H, de Moura MC, Day CP 2006 Non-alcoholic steatohepatitis: from cell biology to clinical practice. J. Hepatol. 44: 197-208. *

• Cortez-Pinto H, Ermelinda Camilo M 2004 Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract. Res. Clin. Gastroenterol. 18: 1089-1104.

• Cotler SJ, Kanji K, Keshavarzian A, Jensen DM, Jakate S 2004 Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J. Clin. Gastroenterol. 38: 801-804.

• Cotrim HP, Parana R, Braga E, Lyra L 2000 Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am. J. Gastroenterol. 95: 3018-3019. *

• Crabb DW 1993 Recent developments in alcoholism: the liver. Recent Dev. Alcohol. 11: 207-230.

• Cua IH, George J 2005 Non-alcoholic fatty liver disease. Hosp. Med. 66: 106-111.

• Cubelic S, Misak Z, Gasparov S, Kolacek S 2004 Nonalcoholic steatohepatitis in children. Lijec. Vjesn. 126: 197-200.

• Czaja AJ 1998 Frequency and significance of phenotypes for alpha1-antitrypsin deficiency in type 1 autoimmune hepatitis. Dig. Dis. Sci. 43: 1725-1731. *

• Czaja AJ 1997 Recurrence of nonalcoholic steatohepatitis after liver transplantation. Liver Transpl. Surg. 3: 185-186.

• Czaja AJ, Carpenter HA, Santrach PJ, Moore SB 1998 Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J. Hepatol. 29: 198-206. *

• Das K, Kar P 2005 Non-alcoholic steatohepatitis. J. Assoc. Physicians India 53: 195-199.

• Daubioul CA, Horsmans Y, Lambert P, Danse E, Delzenne NM 2005 Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur. J. Clin. Nutr. 59: 723-726.

• Day CP 2006 Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int. 26: 1021-1028. *

• de Oliveira CP, de Mello ES, Alves VA, Saviero SM, Strauss E 2007 Changes in histological criteria lead to different prevalences of nonalcoholic steatohepatitis in severe obesity. Ann. Hepatol. 6: 255-261. *

• de Oliveira CP, Stefano JT, de Lima VM, de Sa SV, Simplicio FI, de Mello ES, Correa-Giannella ML, Alves VA, Laurindo FR, de Oliveira MG, Giannella-Neto D, Carrilho FJ 2006 Hepatic gene expression profile associated with non-alcoholic steatohepatitis protection by S-nitroso-N-acetylcysteine in ob/ob mice. J. Hepatol. 45: 725-733. *

• de Oliveira CP, Stefano JT, de Siqueira ER, Silva LS, de Campos Mazo DF, Lima VM, Furuya CK, Mello ES, Souza FG, Rabello F, Santos TE, Nogueira MA, Caldwell SH, Alves VA, Carrilho FJ 2008 Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol. Res. 38: 159-165. *

• Deng QG, She H, Cheng JH, French SW, Koop DR, Xiong S, Tsukamoto H 2005 Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 42: 905-914. *

• Denk H 2004 Pathology of portal hypertension. J. Gastroenterol. Hepatol. 19: S346-S348. *

• Denk H, Stumptner C, Fuchsbichler A, Zatloukal K 2004 Mallory bodies and liver diseases. J. Gastroenterol. Hepatol. 19: S349-S352. *

• Diakou MC, Liberopoulos EN, Mikhailidis DP, Tsianos EV, Burroughs AK, Elisaf MS 2007 Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. Scand. J. Gastroenterol. 42: 139-147. *

• Diehl AM 2005 Role of the immune system in the pathogenesis of nonalcoholic steatohepatitis. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 78. *

• Diehl AM, Li ZP, Lin HZ, Yang SQ 2005 Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 54: 303-306. *

• Dixon JB 2007 Surgical treatment for obesity and its impact on non-alcoholic steatohepatitis. Clin. Liver Dis.11: 141-154.

• Dixon JB, Bhathal PS, Hughes NR, O'Brien PE 2004 Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss Hepatology 39: 1647-1654. *

• Dong H, Wang J, Hirose A, Nozaki Y, Takahashi M, Ono M, Akisawa N, Iwasaki S, Saibara T, Onishi S 2007 The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population? J. Hepatol. 46: 915-920. *

• Duclos-Vallee JC, Yilmaz F, Johanet C, Roque-Afonso AM, Gigou M, Trichet C, Feray C, Ballot E, Dussaix E, Castaing D, Bismuth H, Samuel D, Guettier C 2005 Could post-liver transplantation course be helpful for the diagnosis of so called cryptogenic cirrhosis? Clin. Transplant. 19: 591-599. *

• Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, Zala JF, Helbling B, Steuerwald M, Zimmermann A; Swiss Association for the Study of the Liver 2006 Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 4: 1537-1543.

• Dunn W, Angulo P, Sanderson S, Jamil LH, Stadheim L, Rosen C, Malinchoc M, Kamath PS, Shah VH 2006 Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology 131: 1057-1063. *

• Duseja A, Murlidharan R, Bhansali A, Sharma S, Das A, Das R, Chawla Y 2004 Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis - a preliminary report. Indian J. Gastroenterol. 23: 12-15. *

• Duseja A, Nanda M, Das A, Das R, Bhansali A, Chawla Y 2004 Prevalence of obesity, diabetes mellitus and hyperlipidaemia in patients with cryptogenic liver cirrhosis. Trop. Gastroenterol. 25: 15-17.

• Edmison J, McCullough AJ 2007 Pathogenesis of non-alcoholic steatohepatitis: human data. Clin. Liver Dis.11: 75-104.

• Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S 2006 Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44: 865-873. *

• El-Zayadi AR 2008 Hepatic steatosis: a benign disease or a silent killer. World J. Gastroenterol. 14: 4120-4126. *

• Elias E 2004 Hepatology highlights. Hepatology 39: 1467-1468. *

• Elias E 2005 Hepatology highlights. Hepatology 42: 1241-1242. *

• Ersoz G, Gunsar F, Karasu Z, Akay S, Batur Y, Akarca US 2005 Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk. J. Gastroenterol. 16: 124-128. *

• Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ 2001 Clinical features and natural history of nonalcoholic steatosis syndromes. Semin. Liver Dis. 21: 17-26.

• Fan JG, Zhong L, Tia LY, Xu ZJ, Li MS, Wang GL 2005 Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. World J. Gastroenterol. 11: 2346-2350. *

• Fargion S, Mattioli M, Fracanzani AL, Fiorelli G 2000 Iron and liver diseases. Can. J. Gastroenterol. 14 Suppl. D: 89D-92D.

• Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, Taioli E, Valenti L, Fiorelli G 2001 Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am. J. Gastroenterol. 96: 2448-2455. *

• Farhadi A, Gundlapalli S, Shaikh M, Frantzides C, Harrell L, Kwasny MM, Keshavarzian A 2008 Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int. 28: 1026-1033. *

• Farrell GC 2002 Drugs and steatohepatitis. Semin. Liver Dis. 22: 185-194.

• Farrell GC, Larter CZ 2006 Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43: S99-S112. *

• Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C 2004 Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40: 820-826. *

• Feher J, Lengyel G 2003 A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). J. Int. Med. Res. 31: 537-551.

• Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ 2003 Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125: 437-443. *

• Feldstein AE, Gores GJ 2005 Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front. Biosci. 10: 3093-3099.

• Fickert P, Moustafa T, Fuchsbichler A, Claudel T, Halilbasic E, Kratky D, Zatloukal K, Denk H, Trauner M 2008 Differential effects of ursodeoxycholic acid (UDCA) and sidechain-shortened norUDCA in the treatment of fatty liver and atherosclerosis. Falk Symposium 165: XX International Bile Acid Meeting. Bile Acid Biology and Therapeutic Actions. June 13-14, 2008, Amsterdam, Netherlands, p. 54. *

• Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L 2007 Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med. 13: 298-309. *

• Fisher CD, Jackson JP, Lickteig AJ, Augustine LM, Cherrington NJ 2008 Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch. Toxicol. May 17 [Epub ahead of print]. *

• Fisher L, Fisher A 2007 Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin. Gastroenterol. Hepatol. 5: 513-520.

• Floreani A, Variola A, Niro G, Premoli A, Baldo V, Gambino R, Musso G, Cassader M, Bo S, Ferrara F, Caroli D, Rizzotto ER, Durazzo M 2008 Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am. J. Gastroenterol. 103: 1959-1965. *

• Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, Bertet J,Couzigou P, de Ledinghen V 2006 Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55: 403-408. *

• Friedman SL 2004 Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 98-105. *

• Fujita K, Yoneda M, Wada K, Mawatari H, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Maeyama S, Saito S, Iwasaki T, Terauchi Y, Nakajima A 2007 Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig. Dis. Sci. 52: 3455-3464. *

• Furuya CK Jr, de Oliveira CP, de Mello ES, Faintuch J, Raskovski A, Matsuda M, Vezozzo DC, Halpern A, Garrido AB Jr, Alves VA, Carrilho FJ 2007 Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J. Gastroenterol. Hepatol. 22: 510-514. *

• Gabeta S, Norman GL, Gatselis N, Liaskos C, Papamichalis PA, Garagounis A, Zachou K, Rigopoulou EI, Dalekos GN 2008 IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. J. Clin. Immunol. 28: 501-511. *

• Galhenage SP, Viiala CH, Olynyk JK 2004 Screening for hemochromatosis: patients with liver disease, families, and populations. Curr. Gastroenterol. Rep. 6: 44-51.

• Gambino R, Cassader M, Pagano G, Durazzo M, Musso G 2007 Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? Hepatology 45: 1097-1107. *

• Gao Y, Song LX, Jiang MN, Ge GY, Jia YJ 2008 Effects of traditional Chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis. Inflammation 31: 121-132.

• Garcia-Galiano D, Sanchez-Garrido MA, Espejo I, Montero JL, Costan G, Marchal T, Membrives A, Gallardo-Valverde JM, Munoz-Castaneda JR, Arevalo E, De la Mata M, Muntane J 2007 IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes. Surg. 17: 493-503.

• Garcia-Ruiz C, Fernandez-Checa JC 2006 Mitochondrial glutathione: hepatocellular survival-death switch. J. Gastroenterol. Hepatol. 21 Suppl. 3: S3-S6. *

• Garcia-Ruiz I, Rodriguez-Juan C, Diaz-Sanjuan T, Del Hoyo P, Colina F, Munoz-Yague T, Solis-Herruzo JA 2006 Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology 44: 581-591. *

• Gaya DR, McLay AL, Oien KA, Spooner RJ, Reilly TG 2004 A tale of two sisters. J. Clin. Pathol. 57: 439-441. *

• George J, Liddle C 2008 Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol. Pharm. 5: 49-59. *

• Georgescu EF, Georgescu M 2007 Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J. Gastrointestin. Liver Dis. 16: 39-46. *

• Ghali P, Lindor KD 2004 Hepatotoxicity of drugs used for treatment of obesity and its comorbidities. Semin. Liver Dis. 24: 389-397.

• Goel R, Boylan B, Gruman L, Newman PJ, North PE, Newman DK 2007 The proinflammatory phenotype of PECAM-1-deficient mice results in atherogenic diet induced-steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G1205-G1214. *

• Gores GJ 2003 Apoptosis and liver diseases. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 25. September 12 - 13. *

• Grant LM, Lisker-Melman M 2004 Nonalcoholic fatty liver disease. Ann. Hepatol. 3: 93-99. *

• Green RM, Flamm S 2002 AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 123: 1367-1384. *

• Grieco A, Forgione A, Miele L, Vero V, Greco AV, Gasbarrini A, Gasbarrini G 2005 Fatty liver and drugs. Eur. Rev. Med. Pharmacol. Sci. 9: 261-263.

• Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, Patel N, Madan A, Amarapurkar A, Hafeezunnisa 2004 Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J. Gastroenterol. Hepatol. 19: 854-858. *

• Gyamfi MA, Damjanov I, French S, Wan YJ 2008 The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury. Biochem. Pharmacol. 75: 981-995. *

• Hanje AJ, Shamp JL, Thomas FB, Meis GM 2006 Thalidomide-induced severe hepatotoxicity. Pharmacotherapy 26: 1018-1022. *

• Harrison SA, Neuschwander-Tetri BA 2004 Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin. Liver Dis. 8: 861-879, ix.

• Hashem RM, Mahmoud MF, El-Moselhy MA, Soliman HM 2008 Interleukin-10 to tumor necrosis factor-alpha ratio is a predictive biomarker in nonalcoholic fatty liver disease: interleukin-10 to tumor necrosis factor-alpha ratio in steatohepatitis. Eur. J. Gastroenterol. Hepatol. 20: 995-1001.

• Hashimoto E, Taniai M, Yatsuji S, Tokushige K, Shiratori K, Yamamoto M, Fuchinoue S 2007 Long-term clinical outcome of living-donor liver transplantation for primary biliary cirrhosis. Hepatol. Res. 37 Suppl. 3: S455-S461. *

• Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjoro K, Aukrust P 2006 Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 44: 1167-1174. *

• Higuchi H, Gores GJ 2003 Mechanisms of liver injury: an overview. Curr. Mol. Med. 3: 483-490.

• Hirano F, Kobayashi A, Makino I 2003 Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates, the hypolipidemic drugs. Int. Immunopharmacol. 3: 225-232.

• Holoman J, Glasa J, Galbavy S, Danis D, Molnarova A, Kazar J, Bednarova A, Misianik J 2002 Serum markers of liver fibrogenesis, and liver histology findings in patients with chronic liver diseases. Bratisl. Lek. Listy. 103: 70-75.

• Honda M, Kawai H, Shirota Y, Yamashita T, Takamura T, Kaneko S 2005 cDNA microarray analysis of autoimmune hepatitis, primary biliary cirrhosis and consecutive disease manifestation. J. Autoimmun. 25: 133-140.

• Houghton WC 2003 Betaine and nonalcoholic steatohepatitis. Am. J. Gastroenterol. 98: 2803. *

• Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D, Lok AS, Conjeevaram HS 2005 One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am. J. Gastroenterol. 100: 1072-1081. *

• Hubscher SG 2006 Histological assessment of non-alcoholic fatty liver disease. Histopathology 49: 450-465. *

• Hubscher SG 2004 Role of liver biopsy in the assessment of non-alcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 16: 1107-1115.

• Iacono OL, Petta S, Venezia G, Di Marco V, Tarantino G, Barbaria F, Mineo C, De Lisi S, Almasio PL , Craxi A 2005 Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease? Am. J. Gastroenterol. 100: 2472-2477. *

• Ichikawa T, Yanagi K, Motoyoshi Y, Hamasaki K, Nakao K, Toriyama K, Eguchi K 2006 Two cases of non-alcoholic steatohepatitis with development of hepatocellular carcinoma without cirrhosis. J. Gastroenterol. Hepatol. 21: 1865-1866. *

• Igolnikov AC, Green RM 2006 Mice heterozygous for the Mdr2 gene demonstrate decreased PEMT activity and diminished steatohepatitis on the MCD diet. J. Hepatol. 44: 586-592. *

• Ikeda H, Suzuki M, Takahashi H, Kobayashi M, Okuse N, Moriya H, Koike J, Maeyama S, Yotsuyanagi H, Itoh F 2006 Hepatocellular carcinoma with silent and cirrhotic non-alcoholic steatohepatitis, accompanying ectopic liver tissue attached to gallbladder. Path. Int. 56: 40-45. *

• Ito M, Suzuki J, Sasaki M, Watanabe K, Tsujioka S, Takahashi Y, Gomori A, Hirose H, Ishihara A, Iwaasa H, Kanatani A 2006 Development of nonalcoholic steatohepatitis model through combination of high-fat diet and tetracycline with morbid obesity in mice. Hepatol. Res. 34: 92-98.

• Ito S, Yukawa T, Uetake S, Yamauchi M 2007 Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. Alcohol Clin. Exp. Res. 31: S83-S87. *

• Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ 2002 Mechanisms of hepatotoxicity. Toxicol. Sci. 65: 166-176. *

• Jansen PL 2005 Nonalcoholic steatohepatitis: diagnosis, pathogenesis, treatment and prognosis. Ned. Tijdschr. Geneeskd. 149: 289-294.

• Jansen PL 2004 Non-alcoholic steatohepatitis. Eur. J. Gastroenterol. Hepatol. 16: 1079-1085.

• Jansen PL 2004 Nonalcoholic steatohepatitis. Neth. J. Med. 62: 217-224. *

• Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM 2008 Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 27: 412-421. *

• Javor ED, Ghany MG, Cochran EK, Oral EA, Depaoli AM, Premkumar A, Kleiner DE, Gorden P 2005 Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 41: 753-760. *

• Jung MK, Cho HJ, Lee HC, Park KS, Seo EH, Jeon SW, Cho CM, Tak WY, Kim SK, Choi YH, Kweon YO 2008 Comparison of transient elastography and hepatic fibrosis assessed by histology in chronic liver disease. Korean J. Gastroenterol. 51: 241-247.

• Kadayifci A, Merriman RB, Bass NM 2007 Medical treatment of non-alcoholic steatohepatitis. Clin. Liver Dis.11: 119-140.

• Kallwitz ER, McLachlan A, Cotler SJ 2008 Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J. Gastroenterol. 14: 22-28. *

• Kamada Y, Matsumoto H, Tamura S, Fukushima J, Kiso S, Fukui K, Igura T, Maeda N, Kihara S, Funahashi T, Matsuzawa Y, Shimomura I, Hayashi N 2007 Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J. Hepatol. 47: 556-564. *

• Kamata Y, Kamimura T, Yoshio T, Hirata D, Masuyama J, Isoda N, Kanai N, Minota S 2003 Systemic lupus erythematosus with steroid induced non-alcoholic steatohepatitis: a case report. Ryumachi 43: 667-671.

• Kaplowitz N 2004 Hepatology highlights. Hepatology 39: 271-272. *

• Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H 2005 Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54: 117-121. *

• Kashireddy PR, Rao MS 2004 Sex differences in choline-deficient diet-induced steatohepatitis in mice. Exp. Biol. Med. (Maywood) 229: 158-162. *

• Kashireddy PV, Rao MS 2004 Lack of peroxisome proliferator-activated receptor a in mice enhances methionine and choline deficient diet-induced steatohepatitis. Hepatol. Res. 30: 104-110.

• Kawada N 2006 Human hepatic stellate cells are resistant to apoptosis: implications for human fibrogenic liver disease. Gut 55: 1073-1074. *

• Keaveny AP, Gordon FD, Khettry U 2005 Post-liver transplantation de novo hepatitis with overlap features. Pathol. Int. 55: 660-664. *

• Keeffe EB, Davis GL 2004 Advances in Liver Disease: Highlights from the 54th Annual Meeting of the American Association for the Study of Liver Diseases, October 24-28, 2003. Rev. Gastroenterol. Disord. 4: 36-42. *

• Kirsch R, Clarkson V, Shephard EG, Marais DA, Jaffer MA, Woodburne VE, Kirsch RE, Hall Pde L 2003 Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J. Gastroenterol. Hepatol. 18: 1272-1282. *

• Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noguchi R, Kaji K, Yoshii J, Yanase K, Namisaki T, Asada K, Yamazaki M, Tsujimoto T, Akahane T, Uemura M, Fukui H 2006 Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 44: 983-991. *

• Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, Adim SB, Yerci O, Memik F 2003 Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can. J. Gastroenterol. 17: 713-718.

• Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ 2005 Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321. *

• Koca SS, Bahcecioglu IH, Poyrazoglu OK, Ozercan IH, Sahin K, Ustundag B 2008 The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation 31: 91-98.

• Koike K 2005 Hepatitis C as a metabolic disease: implication for the pathogenesis of NASH. Hepatol. Res. 33: 145-150.

• Konopelska S, Kienitz T, Hughes B, Pirlich M, Bauditz J, Lochs H, Strasburger CJ, Stewart PM, Quinkler M 2008 Hepatic 11beta-HSD1 mRNA expression in fatty liver and non-alcoholic steatohepatitis. Clin. Endocrinol. (Oxf.) Jul 28 [Epub ahead of print]. *

• Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM 2004 Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J. Hepatol. 41: 592-588. *

• Koteish A, Mae Diehl A 2002 Animal models of steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 16: 679-690.

• Kotlyar DS, Campbell MS, Reddy KR 2006 Recurrence of diseases following orthotopic liver transplantation. Am. J. Gastroenterol. 101: 1370-1378. *

• Krueger KJ, McClain CJ, McClave SA, Dryden GW 2004 Nutritional supplements and alternative medicine. Curr. Opin. Gastroenterol. 20: 130-138.

• Kumar KS, Malet PF 2000 Nonalcoholic steatohepatitis. Mayo Clin. Proc. 75: 733-739. *

• Kunde SS, Lazenby AJ, Clements RH, Abrams GA 2005 Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 42: 650-656. *

• Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Denk H 2008 Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J. Hepatol. 48: 821-828.

• Lalor PF, Faint J, Aarbodem Y, Hubscher SG, Adams DH 2007 The role of cytokines and chemokines in the development of steatohepatitis. Semin. Liver Dis. 27: 173-193.

• Lang L 2006 Phase I/II clinical trial to explore silymarin in chronic liver diseases. Gastroenterology 131: 990. *

• Larter CZ, Yeh MM, Cheng J, Williams J, Brown S, Dela Pena A, Bell-Anderson KS, Farrell GC 2008 Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation. J. Gastroenterol. Hepatol. 23: 267-275. *

• Laurent A, Nicco C, Tran Van Nhieu J, Borderie D, Chereau C, Conti F, Jaffray P, Soubrane O, Calmus Y, Weill B, Batteux F 2004 Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis. Hepatology 39: 1277-1285. *

• Leclercq IA 2007 Pathogenesis of steatohepatitis: insights from the study of animal models. Acta Gastroenterol. Belg. 70: 25-31.

• Leclercq IA, Farrell GC, Sempoux C, Pena AD, Horsmans Y 2004 Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J. Hepatol. 41: 926-934. *

• Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ 2007 Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J. Hepatol. 47: 239-244. *

• Lefkowitch JH 2004 Hepatobiliary pathology. Curr. Opin. Gastroenterol. 20: 188-197.

• Lefkowitch JH 2006 Hepatobiliary pathology. Curr. Opin. Gastroenterol. 22: 198-208.

• Lefkowitch JH 2005 Morphology of alcoholic liver disease. Clin. Liver Dis. 9: 37-53.

• Lefkowitch JH 2003 Hepatobiliary pathology. Curr. Opin. Gastroenterol. 19: 185-193.

• Lefkowitch JH 2008 Hepatobiliary pathology. Curr. Opin. Gastroenterol. 24: 269-277.

• Lefkowitch JH 2007 Hepatobiliary pathology. Curr. Opin. Gastroenterol. 23: 221-231.

• Lefkowitch JH 2002 Liver histopathology. Clin. Liver Dis. 6: xv-xix. *

• Leicester KL, Olynyk JK, Brunt EM, Britton RS, Bacon BR 2006 Differential findings for CD14-positive hepatic monocytes/macrophages in primary biliary cirrhosis, chronic hepatitis C and nonalcoholic steatohepatitis. Liver Int. 26: 559-565. *

• Lemoine M, Barbu V, Girard PM, Kim M, Bastard JP, Wendum D, Paye F, Housset C, Capeau J, Serfaty L 2006 Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS 20: 387-395.

• Lengyel G, Tulassay Z 2006 Antioxidant therapy in chronic liver diseases. Orv. Hetil. 147: 1113-1118.

• Li X, Han de W, Zhao LF, Yin L 2005 Effect of endotoxin on the expression of peroxisome proliferator-activated receptor alpha in the development of nonalcoholic steatohepatitis in rats. Zhonghua Gan Zang Bing Za Zhi 13: 89-91.

• Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, Vance DE 2006 The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab. 3: 321-331. *

• Li Z, Diehl AM 2003 Innate immunity in the liver. Curr. Opin. Gastroenterol. 19: 565-571.

• Li Z, Oben JA, Yang S, Lin H, Stafford EA, Soloski MJ, Thomas SA, Diehl AM 2004 Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis. Hepatology 40: 434-441. *

• Liangpunsakul S, Chalasani N 2003 Treatment of nonalcoholic fatty liver disease. Curr. Treat. Options Gastroenterol. 6: 455-463.

• Lieber CS 2004 New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. Curr. Gastroenterol. Rep. 6: 60-65.

• Lieber CS 2004 CYP2E1: from ASH to NASH. Hepatol. Res. 28: 1-11.

• Lieber CS 2004 The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab. Rev. 36: 511-529.

• Lieber CS, Decarli LM, Leo MA, Mak KM, Ponomarenko A, Ren C, Wang X 2008 Beneficial effects versus toxicity of medium-chain triacylglycerols in rats with NASH. J. Hepatol. 48: 318-326. *

• Lieber CS, Leo MA, Cao Q, Mak KM, Ren C, Ponomarenko A, Wang X, Decarli LM 2007 The combination of S-adenosylmethionine and dilinoleoylphosphatidylcholine attenuates non-alcoholic steatohepatitis produced in rats by a high-fat diet. Nutr. Res. 27: 565-573.

• Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli LM 2004 Model of nonalcoholic steatohepatitis. Am. J. Clin. Nutr. 79: 502-509. *

• Lim LG, Cheng CL, Wee A, Lim SG, Lee YM, Sutedja DS, Da Costa M, Prabhakaran K, Wai CT 2007 Prevalence and clinical associations of posttransplant fatty liver disease. Liver Int. 27: 76-80. *

• Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P 2004 Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39: 770-778. *

• London RM, George J 2007 Pathogenesis of NASH: animal models. Clin. Liver Dis.11: 55-74.

• Lopez Dieguez Puerta M, Casal Esteban V, Barbado Hernandez FJ, Gil Guerrero L, Rodriguez Molinero MA, Larrauri J, Vazquez Rodriguez JJ 2005 Nonalcoholic steatohepatitis, the enigma of bad progress. An. Med. Interna. 22: 85-87.

• Loria P, Lonardo A, Carulli N 2005 Should nonalcoholic fatty liver disease be renamed? Dig. Dis. 23: 72-82.

• Ludtke A, Genschel J, Brabant G, Bauditz J, Taupitz M, Koch M, Wermke W, Worman HJ, Schmidt HH 2005 Hepatic steatosis in Dunnigan-type familial partial lipodystrophy. Am. J. Gastroenterol. 100: 2218-2224. *

• Ludwig J, McGill DB, Lindor KD 1997 Review: nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 12: 398-403.

• Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M 2007 Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11: 119-132. *

• Ma X, Hua J, Mohamood AR, Hamad AR, Ravi R, Li Z 2007 A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology 46: 1519-1529. *

• Maher JJ, Leon P, Ryan JC 2008 Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology 48: 670-678.

• Maheshwari A, Thuluvath PJ 2006 Cryptogenic cirrhosis and NAFLD: are they related? Am. J. Gastroenterol. 101: 664-668. *

• Maier KP 2005 The patient with slightly increased liver function tests. Schweiz. Rundsch. Med. Prax. 94: 139-143.

• Malaguarnera L, Di Rosa M, Zambito AM, dell'Ombra N, Nicoletti F, Malaguarnera M 2006 Chitotriosidase gene expression in Kupffer cells of non-alcoholic fatty liver disease patients. Gut 55: 1313-1320. *

• Malik A, Cheah PL, Hilmi IN, Chan SP, Goh KL 2007 Non-alcoholic fatty liver disease in Malaysia: a demographic, anthropometric, metabolic and histological study. Chin. J. Dig. Dis. 8: 58-64. *

• Marchesini G, Bugianesi E, Forlani G, Marzocchi R, Zannoni C, Vanni E, Manini R, Rizzetto M, Melchionda N 2004 Non-alcoholic steatohepatitis in patients cared in metabolic units. Diabetes Res. Clin. Pract. 63: 143-151.

• Marchesini G, Suppini A, Forlani G 2005 NAFLD treatment: cognitive-behavioral therapy has entered the arena. J. Hepatol. 43: 926-928. *

• Marra F 2004 NASH: are genes blowing the hits? J. Hepatol. 40: 853-856. *

• Martinez-Chantar ML, Corrales FJ, Martinez-Cruz LA, Garcia-Trevijano ER, Huang ZZ, Chen L, Kanel G, Avila MA, Mato JM, Lu SC 2002 Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J. 16: 1292-1294. *

• Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G 1999 The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand. J. Gastroenterol. 34: 85-91. *

• Mathur A, Marine M, Lu D, Swartz-Basile DA, Saxena R, Zyromski NJ, Pitt HA 2007 Nonalcoholic fatty pancreas disease. HPB (Oxford) 9: 312-318. *

• Matsumoto T, Suzuki N, Watanabe H, Irie M, Iwata K, Anan A, Nakane H, Yoshikane M, Nishizawa S, Sohda T, Sakisaka S 2004 Nonalcoholic steatohepatitis associated with psoriasis vulgaris. J. Gastroenterol. 39: 1102-1105. *

• Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, Nakanuma Y, Miyamoto K, Kaneko S 2007 Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46: 1392-1403.

• Mayo MJ, Mosby JM, Jeyarajah R, Combes B, Khilnani S, Al-Halimi M, Handem I, Grammer AC, Lipsky PE 2006 The relationship between hepatic immunoglobulin production and CD154 expression in chronic liver diseases. Liver Int. 26: 1871-96. *

• McClain CJ, Mokshagundam SP, Barve SS, Song Z, Hill DB, Chen T, Deaciuc I 2004 Mechanisms of non-alcoholic steatohepatitis. Alcohol 34: 67-79.

• McCullough AJ 2006 Thiazolidinediones for nonalcoholic steatohepatitis - promising but not ready for prime time. N. Engl. J. Med. 355: 2361-2363. *

• Mehta K, Van Thiel DH, Shah N, Mobarhan S 2002 Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr. Rev. 60: 289-293.

• Mendes FD, Lindor KD 2005 Recent advances in the treatment of non-alcoholic fatty liver disease. Expert Opin. Investig. Drugs 14: 29-35.

• Mendez-Sanchez N, Motola-Kuba D, Bahena-Aponte J, Chavez-Tapia N, Pichardo-Bahena R, Uribe M 2003 Hypertransaminasemia and severe hepatic steatosis without inflammation. A case report. Ann. Hepatol. 2: 183-185. *

• Mendez-Sanchez N, Zamora-Valdes D, Pichardo-Bahena R, Barredo-Prieto B, Ponciano-Rodriguez G, Bermejo-Martinez L, Chavez-Tapia NC, Baptista-Gonzalez HA, Uribe M 2007 Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Liver Int. 27: 215-219. *

• Menon KVN, Angulo P, Lindor KD 2001 Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. Am. J. Gastroenterol. 96: 1631-1634. *

• Mensink RP, Plat J, Schrauwen P 2008 Diet and nonalcoholic fatty liver disease. Curr. Opin. Lipidol. 19: 25-29.

• Merriman RB, Aouizerat BE, Bass NM 2006 Genetic influences in nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 40 Suppl. 1: S30-S33.

• Milke Garcia Mdel P 2005 Ghrelin: beyond hunger regulation. Rev. Gastroenterol. Mex. 70: 465-474.

• Mishra P, Younossi ZM 2007 Current treatment strategies for non-alcoholic fatty liver disease (NAFLD). Curr. Drug Discov. Technol. 4: 133-140.

• Moreno Sanchez D 2005 Pathogenesis of primary nonalcoholic fatty liver disease. Med. Clin. (Barc.) 124: 668-677.

• Morita Y, Ueno T, Sasaki N, Tateishi Y, Nagata E, Kage M, Sata M 2005 Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. Hepatogastroenterology 52: 1338-1343.

• Moseley RH 2005 Progress in understanding the pathogenesis of nonalcoholic fatty liver disease. Hepatology 41: 204. *

• Mulhall BP, Younossi ZM 2004 Nonalcoholic steatohepatitis. Curr. Treat. Options Gastroenterol. 7: 423-430.

• Muller T, Langner C, Fuchsbichler A, Heinz-Erian P, Ellemunter H, Schlenck B, Bavdekar AR, Pradhan AM, Pandit A, Muller-Hocker J, Melter M, Kobayashi K, Nagasaka H, Kikuta H, Muller W, Tanner MS, Sternlieb I, Zatloukal K, Denk H 2004 Immunohistochemical analysis of Mallory bodies in Wilsonian and non-Wilsonian hepatic copper toxicosis. Hepatology 39: 963-969. *

• Musso G, Gambino R, Biroli G, Carello M, Faga E, Pacini G, De Michieli F, Cassader M, Durazzo M, Rizzetto M, Pagano G 2005 Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 100: 2438-2446. *

• Musso G, Gambino R, De Michieli F, Biroli G, Premoli A, Pagano G, Bo S, Durazzo M, Cassader M 2007 Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake. Am. J. Clin. Nutr. 86: 661-671. *

• Nagata K, Suzuki H, Sakaguchi S 2007 Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J. Toxicol. Sci. 32: 453-468. *

• Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP 2004 Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment. Pharmacol. Ther. 20: 23-28. *

• Nakajima A, Yoneda M, Takahashi H, Fujisawa N, Wada K 2005 The roles of PPARs in digestive diseases. Nippon Rinsho 63: 665-671.

• Nakanishi Y, Tsuneyama K, Fujimoto M, Salunga TL, Nomoto K, An JL, Takano Y, Iizuka S, Nagata M, Suzuki W, Shimada T, Aburada M, Nakano M, Selmi C, Gershwin ME 2008 Monosodium glutamate (MSG): a villain and promoter of liver inflammation and dysplasia. J. Autoimmun. 30: 41-49. *

• Nakano S, Nagasawa T, Ijiro T, Inada Y, Tamura T, Maruyama K, Kuroda J, Yamazaki Y, Kusama H, Shibata N 2008 Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line. Hepatol. Res. May 28 [Epub ahead of print]. *

• Namikawa C, Shu-Ping Z, Vyselaar JR, Nozaki Y, Nemoto Y, Ono M, Akisawa N, Saibara T, Hiroi M, Enzan H, Onishi S 2004 Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J. Hepatol. 40: 781-786. *

• Nanda K 2004 Non-alcoholic steatohepatitis in children. Pediatr. Transplant. 8: 613-618. *

• Nanji AA 2004 Animal models of nonalcoholic fatty liver disease and steatohepatitis. Clin. Liver Dis. 8: 559-574, ix.

• Nehra V, Angulo P, Buchman AL, Lindor KD 2001 Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig. Dis. Sci. 46: 2347-2352. *

• Neuberger J 2005 Chronic allograft dysfunction: diagnosis and management. Is it always progressive? Liver Transpl. 11: S63-S68. *

• Neuschwander-Tetri BA 1998 Nonalcoholic steatohepatitis. Clin. Liver Dis. 2: 149-173.

• Neuschwander-Tetri BA 2002 Evolving pathophysiologic concepts in nonalcoholic steatohepatitis. Curr. Gastroenterol. Rep. 4: 31-36.

• Neuschwander-Tetri BA 2000 Nonalcoholic steatohepatitis: an evolving diagnosis. Can. J. Gastroenterol. 14: 321-326.

• Neuschwander-Tetri BA 2001 Fatty liver and nonalcoholic steatohepatitis. Clin. Cornerstone 3: 47-57.

• Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR 2003 Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38: 1008-10017. *

• Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR 2003 Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J. Hepatol. 38: 434-440. *

• Neuschwander-Tetri BA, Caldwell SH 2003 Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37: 1202-1219. *

• Niwa H, Sasaki M, Haratake J, Kasai T, Katayanagi K, Kurumaya H, Masuda S, Minato H, Zen Y, Uchiyama A, Miwa A, Saito K, Sudo Y, Nakanuma Y 2007 Clinicopathological significance of antinuclear antibodies in non-alcoholic steatohepatitis. Hepatol. Res. 37: 923-931. *

• Nobili V, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A, Fruhwirth R, Marcellini M, Pinzani M 2008 Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 48: 442-448.

• Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, Renner EL, Clavien PA 2007 Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. Gastroenterology 133: 608-618. *

• Obara N, Ueno Y, Fukushima K, Nakagome Y, Kakazu E, Kimura O, Wakui Y, Kido O, Ninomiya M, Kogure T, Inoue J, Kondo Y, Shiina M, Iwasaki T, Yamamoto T, Shimosegawa T 2008 Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases. J. Gastroenterol. 43: 720-728.

• Ogawa Y, Murata Y, Saibara T, Nishioka A, Kariya S, Yoshida S 2003 Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate. Oncol. Rep. 10: 1473-1478.

• Ohnishi T, Ogawa Y, Saibara T, Nishioka A, Kariya S, Fukumoto M, Onishi S, Yoshida S 2005 CYP17 polymorphism and tamoxifen-induced hepatic steatosis. Hepatol. Res. 33: 178-180.

• Ong JP, Younossi ZM 2005 Approach to the diagnosis and treatment of nonalcoholic fatty liver disease. Clin. Liver Dis. 9: 617-634.

• Ong JP, Younossi ZM 2007 Epidemiology and natural history of NAFLD and NASH. Clin. Liver Dis.11: 1-16.

• Orlando R, Azzalini L, Orando S, Lirussi F 2007 Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst. Rev. 1: CD005160. *

• Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, Uno M, Akahori H, Misu H, Sakurai M, Zen Y, Nakanuma Y, Kaneko S 2007 Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 132: 282-293. *

• Ouazzani-Chahdi A, Elimadi A, Chabli A, Spenard J, Colin P, Haddad PS 2007 Combining ursodeoxycholic acid or its NO-releasing derivative NCX-1000 with lipophilic antioxidants better protects mouse hepatocytes against amiodarone toxicity. Can. J. Physiol. Pharmacol. 85: 233-242.

• Oz HS, Im HJ, Chen TS, de Villiers WJ, McClain CJ 2006 Glutathione-enhancing agents protect against steatohepatitis in a dietary model. J. Biochem. Mol. Toxicol. 20: 39-47. *

• Papakyriakou P, Tzardi M, Valatas V, Kanavaros P, Karydi E, Notas G, Xidakis C, Kouroumalis E 2002 Apoptosis and apoptosis related proteins in chronic viral liver disease. Apoptosis 7: 133-141. *

• Park JY, Chong AY, Cochran EK, Kleiner DE, Haller MJ, Schatz DA, Gorden P 2008 Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. J. Clin. Endocrinol. Metab. 93: 26-31. *

• Parola M, Novo E 2005 Nrf1 gene expression in the liver: a single gene linking oxidative stress to NAFLD, NASH and hepatic tumours. J. Hepatol. 43: 1096-1097. *

• Pessayre D 2007 Role of mitochondria in non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 22 Suppl. 1: S20-S27.

• Pessayre D, Fromenty B, Mansouri A 2004 Mitochondrial injury in steatohepatitis. Eur. J. Gastroenterol. Hepatol. 16: 1095-1105.

• Pessayre D, Mansouri A, Fromenty B 2002 Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 282: G193-G199. *

• Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Makhviladze M, Huyghe M, Hecht D, Oltersdorf T, Shapiro DA 2007 Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 46: 324-329. *

• Poonawala A, Nair SP, Thuluvath PJ 2000 Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32: 689-692. *

• Portincasa P, Grattagliano I, Palmieri VO, Palasciano G 2005 Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management. Clin. Biochem. 38: 203-217. *

• Portincasa P, Grattagliano I, Palmieri VO, Palasciano G 2006 Current pharmacological treatment of nonalcoholic fatty liver. Curr. Med. Chem. 13: 2889-2900.

• Portincasa P, Grattagliano I, Palmieri VO, Palasciano G 2005 The emerging problem of nonalcoholic steatohepatitis (NASH). Rom. J. Gastroenterol. 14: 43-51.

• Qian Y, Fan JG 2005 Obesity, fatty liver and liver cancer. Hepatobiliary Pancreat. Dis. Int. 4: 173-177. *

• Rahman SM, Schroeder-Gloeckler JM, Janssen RC, Jiang H, Qadri I, Maclean KN, Friedman JE 2007 CCAAT/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis. Hepatology 45: 1108-1117. *

• Ramesh S, Sanyal AJ 2005 Evaluation and management of non-alcoholic steatohepatitis. J. Hepatol. 42 Suppl.: S2-S12. *

• Rangnekar AS, Lammert F, Igolnikov A, Green RM 2006 Quantitative trait loci analysis of mice administered the methionine-choline deficient dietary model of experimental steatohepatitis. Liver Int. 26: 1000-1005. *

• Rao MS, Papreddy K, Musunuri S, Okonkwo A 2002 Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisome proliferator-activated receptor alpha ligand in rats. In Vivo 16: 145-152.

• Rao MS, Reddy JK 2001 Peroxisomal beta-oxidation and steatohepatitis. Semin. Liver Dis. 21: 43-55.

• Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T 2005 Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128: 1898-1906. *

• Ratziu V, Poynard T 2006 Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology 44: 802-805. *

• Rector RS, Thyfault JP, Wei Y, Ibdah JA 2008 Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J. Gastroenterol. 14: 185-192. *

• Reddy JK, Sambasiva Rao M 2006 Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G852-G858. *

• Reid AE 2001 Nonalcoholic steatohepatitis. Gastroenterology 121: 710-723. *

• Reid BM, Sanyal AJ 2004 Evaluation and management of non-alcoholic steatohepatitis. Eur. J. Gastroenterol. Hepatol. 16: 1117-1122.

• Ribeiro PS, Cortez-Pinto H, Sola S, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME, Rodrigues CM 2004 Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am. J. Gastroenterol. 99: 1708-1717. *

• Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM 2008 Mechanisms of steatohepatitis in mice fed a lipogenic methionine choline deficient (MCD) diet. J. Lipid Res. 49: 1068-1076. *

• Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M 2007 Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 47: 571-579. *

• Roberts EA 2007 Non-alcoholic steatohepatitis in children. Clin. Liver Dis.11: 155-172.

• Roberts EA 2003 Nonalcoholic steatohepatitis in children. Curr. Gastroenterol. Rep. 5: 253-259.

• Robertson G, Leclercq I, Farrell GC 2001 Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am. J. Physiol. Gastrointest. Liver Physiol. 281: G1135-G1139. *

• Rodriguez-Hernandez H, Gonzalez JL, Marquez-Ramirez MD, Flores-Hernandez M, Rodriguez-Moran M, Guerrero-Romero F 2008 Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes. Eur. J. Gastroenterol. Hepatol. 20: 399-403.

• Rosa H, Parise ER 2008 Is there a place for serum laminin determination in patients with liver disease and cancer? World J. Gastroenterol. 14: 3628-3632. *

• Roskams T 2006 Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 25: 3818-3822. *

• Rosmorduc O, Hermelin B, Boelle PY, Poupon RE, Poupon R, Chazouilleres O 2004 ABCB4 gene mutations and primary sclerosing cholangitis. Gastroenterology 126: 1220-1222. *

• Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J 2008 The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl. Int. 21: 459-465. *

• Rubio A, Guruceaga E, Vazquez-Chantada M, Sandoval J, Martinez-Cruz LA, Segura V, Sevilla JL, Podhorski A, Corrales FJ, Torres L, Rodriguez M, Aillet F, Ariz U, Caballeria J, Martin-Duce A, Lu SC, Martinez-Chantar ML, Mato JM 2007 Gene-pathway identification associated with non-alcoholic steatohepatitis. J. Hepatol. 46: 708-718. *

• Saab S, Cho D, Lassman RC, Gajjar NA, Ghobrial M, Busuttil RW 2005 Recurrent non-alcoholic steatohepatitis in a living related liver transplant recipient. J. Hepatol. 42: 148-149. *

• Saibara T, Namikawa C, Zhang SP, Nozaki Y, Yoshihisa N, Ono M, Akisawa N, Iwasaki S, Onishi S, Hiroi M, Enzan H 2004 Functional genetic polymorphisms of microsomal triglyceride transfer protein and manganase-SOD in nonalcoholic steatohepatitis and primary biliary cirrhosis. J. Hepatol. 40 Suppl. 1: 175.

• Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, Shiroma J, Toyama A, Nakayoshi T, Kinjo F, Saito A 2005 Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J. Gastroenterol. 11: 255-259. *

• Salt WB 2nd 2004 Nonalcoholic fatty liver disease (NAFLD): a comprehensive review. J. Insur. Med. 36: 27-41.

• Santamaria E, Avila MA, Latasa MU, Rubio A, Martin-Duce A, Lu SC, Mato JM, Corrales FJ 2003 Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proc. Natl. Acad. Sci. U.S.A. 100: 3065-3070. *

• Sanyal AJ 2005 Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 46-53. *

• Sanyal AJ 2001 Insulin resistance and nonalcoholic steatohepatitis: fat or fiction? Am. J. Gastroenterol. 96: 274-276. *

• Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN 2001 Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120: 1183-1192. *

• Sasaki M, Ikeda H, Nakanuma Y 2008 Activation of ATM signaling pathway is involved in oxidative stress-induced expression of mito-inhibitory p21(WAF1/Cip1) in chronic non-suppurative destructive cholangitis in primary biliary cirrhosis: an immunohistochemical study. J. Autoimmun. 31: 73-78.

• Sasaki N, Ueno T, Morita Y, Nagata E, Sata M 2006 Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH). Hepatogastroenterology 53: 678-681.

• Sass DA, Chang P, Chopra KB 2005 Nonalcoholic fatty liver disease: a clinical review. Dig. Dis. Sci. 50: 171-180. *

• Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, Sarin SK 2004 Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99: 1946-1952. *

• Sato K, Ueda Y, Ueno K, Okamoto K, Iizuka H, Katsuda S 2005 Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. Virchows Arch. 447: 996-999. *

• Savransky V, Bevans S, Nanayakkara A, Li J, Smith PL, Torbenson MS, Polotsky VY 2007 Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G871-G877. *

• Sazci A, Akpinar G, Aygun C, Ergul E, Senturk O, Hulagu S 2008 Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. Dig. Dis. Sci. May 9 [Epub ahead of print]. *

• Sazci A, Ergul E, Aygun C, Akpinar G, Senturk O, Hulagu S 2008 Methylenetetrahydrofolate reductase gene polymorphisms in patients with nonalcoholic steatohepatitis (NASH). Cell. Biochem. Funct. 26: 291-296.

• Schartman J, Weinstein J 2006 Intermittent disconjugate gaze: a novel finding in nonalcoholic steatohepatitis. Hepatology 43: 882-883. *

• Schattenberg JM, Singh R, Wang Y, Lefkowitch JH, Rigoli RM, Scherer PE, Czaja MJ 2006 Jnk1 but not jnk2 promotes the development of steatohepatitis in mice. Hepatology 43: 163-172. *

• Schwabe RF, Seki E, Brenner DA 2006 Toll-like receptor signaling in the liver. Gastroenterology 130: 1886-1900. *

• Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, Lavine JE 2005 Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42: 641-649. *

• Seki E, Brenner DA 2007 The role of NF-kappaB in hepatocarcinogenesis: promoter or suppressor? J. Hepatol. 47: 307-309. *

• Sepulveda-Flores RN, Vera-Cabrera L, Flores-Gutierrez JP, Maldonado-Garza H, Salinas-Garza R, Zorrilla-Blanco P, Bosques-Padilla FJ 2002 Obesity-related non-alcoholic steatohepatitis and TGF-beta1 serum levels in relation to morbid obesity. Ann. Hepatol. 1: 36-39. *

• Serfaty L 2007 Pioglitazone: the beginning of a new era for NASH? J. Hepatol. 47: 160-162. *

• Seyam M, Neuberger JM, Gunson BK, Hubscher SG 2007 Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence. Liver Transpl. 13: 966-974. *

• Sharma MR, Polavarapu R, Roseman D, Patel V, Eaton E, Kishor PB, Nanji AA 2006 Transcriptional networks in a rat model for nonalcoholic fatty liver disease: a microarray analysis. Exp. Mol. Pathol. 81: 202-210. *

• Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M, Tsutsumi M, Takase S 2007 Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7s level to predict the early stage of nonalcoholic steatohepatitis. Am. J. Gastroenterol. 102: 1931-1938. *

• Shiri-Sverdlov R, Wouters K, van Gorp PJ, Gijbels MJ, Noel B, Buffat L, Staels B, Maeda N, van Bilsen M, Hofker MH 2006 Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J. Hepatol. 44: 732-741. *

• Siatkosky LL, Shermock KM, Younossi ZM 2002 Investigational pharmacologic treatment for liver disease. Expert Opin. Investig. Drugs 11: 1281-1293.

• Simonovic-Babic J, Delic D, Svirtlih N, Dordevic M 2004 Elevated aminotransferse levels - diagnostic approach. Med. Pregl. 57: 429-433.

• Solga SF 2003 Probiotics can treat hepatic encephalopathy. Med. Hypotheses 61: 307-313. *

• Sorbi D, Boynton J, Lindor KD 1999 The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am. J. Gastroenterol. 94: 1018-1022. *

• Sorbi D, McGill DB, Thistle JL, Therneau TM, Henry J, Lindor KD 2000 An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am. J. Gastroenterol. 95: 3206-3210. *

• Soresi M, Bonfissuto G, Magliarisi C, Riili A, Terranova A, Di Giovanni G, Bascone F, Carroccio A, Tripi S, Montalto G 2003 Ultrasound detection of abdominal lymph nodes in chronic liver diseases. A retrospective analysis. Clin. Radiol. 58: 372-377. *

• Sorrentino P, Tarantino G, Conca P, Perrella A, Terracciano ML, Vecchione R, Gargiulo G, Gennarelli N, Lobello R 2004 Silent non-alcoholic fatty liver disease-a clinical-histological study. J. Hepatol. 41: 751-757. *

• Sreekumar R, Rosado B, Rasmussen D, Charlton M 2003 Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 38: 244-251. *

• Stefano JT, de Oliveira CP, Correa-Giannella ML, de Lima VM, de Sa SV, de Oliveira EP, de Mello ES, Giannella-Neto D, Alves VA, Carrilho FJ 2007 Nonalcoholic steatohepatitis (NASH) in OB/OB mice treated with Yo Jyo Hen Shi Ko (YHK): effects on peroxisome proliferator-activated receptors (PPARs) and microsomal triglyceride transfer protein (MTP). Dig. Dis. Sci. 52: 3448-3454. *

• Strnad P, Zatloukal K, Stumptner C, Kulaksiz H, Denk H 2008 Mallory-Denk bodies: lessons from keratin-containing hepatic inclusion bodies. Biochim. Biophys. Acta Sep 6 [Epub ahead of print].

• Struben VM, Hespenheide EE, Caldwell SH 2000 Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am. J. Med. 108: 9-13. *

• Su WJ, Chen HL, Lai HS, Ni YH, Chang MH 2007 Pancreaticobiliary anomalies is the leading cause of childhood recurrent pancreatitis. J. Formos. Med. Assoc. 106: 119-125. *

• Sugimoto M, Sadamoto T, Nonaka H 2003 Clinical and pathological differences between alcoholic hepatitis and non-alcoholic steatohepatitis. Nihon Arukoru Yakubutsu Igakkai Zasshi 38: 34-45.

• Sundaram SS, Whitington PF, Green RM 2005 Steatohepatitis develops rapidly in transgenic mice over-expressing Abcb11 fed a methionine-choline deficient diet. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G1321-G1327. *

• Suriawinata A, Fiel MI 2004 Liver pathology in obesity. Semin. Liver Dis. 24: 363-370.

• Suzuki A, Lymp J, Sauver JS, Angulo P, Lindor K 2006 Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int. 26: 1209-1216. *

• Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, Marzioni M, De Minicis S, Nobili L, Salzano R, Omenetti A, Pacetti D, Sigmund S, Benedetti A, Casini A 2006 A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am. J. Pathol. 169: 846-860. *

• Szabo G, Velayudham A, Romics L Jr, Mandrekar P 2005 Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of Toll-like receptors 2 and 4. Alcohol Clin. Exp. Res. 29: 140S-145S.

• Tacikowski T, Nowicka G, Bujko J, Walewska-Zielecka B, Dzieniszewski J 2005 Influence of high-fat diet, rosiglitazone on lipid profile, insulin resistance and liver steatosis development. Pol. Arch. Med. Wewn. 113: 213-222.

• Takahashi Y, Iida K, Takahashi K, Yoshioka S, Fukuoka H, Takeno R, Imanaka M, Nishizawa H, Takahashi M, Seo Y, Hayashi Y, Kondo T, Okimura Y, Kaji H, Kitazawa R, Kitazawa S, Chihara K 2007 Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology 132: 938-943. *

• Tanaka N, Aoyama T 2006 PPAR and NASH. Nippon Rinsho 64: 1089-1094.

• Tanaka N, Ichijo T, Okiyama W, Mutou H, Misawa N, Matsumoto A, Yoshizawa K, Tanaka E, Kiyosawa K 2006 Laparoscopic findings in patients with nonalcoholic steatohepatitis. Liver Int. 26: 39-45. *

• Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T 2008 Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 42: 413-418.

• Tanaka N, Tanaka E, Sheena Y, Komatsu M, Okiyama W, Misawa N, Muto H, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Horiuchi A, Kiyosawa K 2006 Useful parameters for distinguishing nonalcoholic steatohepatitis with mild steatosis from cryptogenic chronic hepatitis in the Japanese population. Liver Int. 26: 956-963. *

• Tannapfel A, Reinacher-Schick A 2008 Chemotherapy associated hepatotoxicity in the treatment of advanced colorectal cancer (CRC). Z. Gastroenterol. 46: 435-440.

• Tarantino G, Saldalamacchia G, Conca P, Arena A 2007 Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J. Gastroenterol. Hepatol. 22: 293-303. *

• te Sligte K, Bourass I, Sels JP, Driessen A, Stockbrugger RW, Koek GH 2004 Non-alcoholic steatohepatitis: review of a growing medical problem. Eur. J. Intern. Med. 15: 10-21. *

• Tellez-Avila FI, Sanchez-Avila F, García-Saenz-de-Sicilia M, Chavez-Tapia NC, Franco-Guzman AM, Lopez-Arce G, Cerda-Contreras E, Uribe M 2008 Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J. Gastroenterol. 14: 4771-4775. *

• Tiegs G 2007 Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury. Z. Gastroenterol. 45: 63-70.

• Tilg H, Diehl AM 2000 Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 343: 1467-1476. *

• Tilg H, Kaser A 2005 Treatment strategies in nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 148-155. *

• Toblli JE, Munoz MC, Cao G, Mella J, Pereyra L, Mastai R 2008 ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring) 16: 770-776. *

• Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K 2007 Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J. Hepatol. 46: 1104-1110. *

• Tolman KG, Dalpiaz AS 2007 Treatment of non-alcoholic fatty liver disease. Ther. Clin. Risk Manag. 3: 1153-1163.

• Tomita K, Oike Y, Teratani T, Taguchi T, Noguchi M, Suzuki T, Mizutani A, Yokoyama H, Irie R, Sumimoto H, Takayanagi A, Miyashita K, Akao M, Tabata M, Tamiya G, Ohkura T, Hibi T 2008 Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology 48: 458-473.

• Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, Kitamura N,Toda K, Kaneko T, Horie Y, Han JY, Kato S, Shimoda M, Oike Y, Tomizawa M, Makino S, Ohkura T, Saito H, Kumagai N, Nagata H, Ishii H, Hibi T 2006 Tumour necrosis factor-alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 55: 415-424. *

• Torer N, Ozenirler S, Yucel A, Bukan N, Erdem O 2007 Importance of cytokines, oxidative stress and expression of BCL-2 in the pathogenesis of non-alcoholic steatohepatitis. Scand. J. Gastroenterol. 42: 1095-1101. *

• Torres DM, Harrison SA 2008 Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 134: 1682-1698. *

• Tran TT 2003 Liver transplantation: a clinical update. 54th Annual Meeting of the American Association for the Study of Liver Diseases.

• Trappoliere M, Tuccillo C, Federico A, Di Leva A, Niosi M, D'Alessio C, Capasso R, Coppola F, Dauria M, Loguercio C 2005 The treatment of NAFLD. Eur. Rev. Med. Pharmacol. Sci. 9: 299-304.

• Trauner M, Graziadei IW 1999 Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment. Pharmacol. Ther. 13: 979-996. *

• Tsochatzis E, Papatheodoridis GV, Archimandritis AJ 2006 The evolving role of leptin and adiponectin in chronic liver diseases. Am. J. Gastroenterol. 101: 2629-2640. *

• Tsukamoto H, She H, Hazra S, Cheng J, Wang J 2008 Fat paradox of steatohepatitis. J. Gastroenterol. Hepatol. 23 Suppl. 1: S104-S107. *

• Umar RK, Rinella ME 2006 An update on nonalcoholic fatty liver disease. Gastroenterology & Hepatology Annual Review Vol. 1, June 2006, p. 94-98. *

• Uno M, Kurita S, Misu H, Ando H, Ota T, Matsuzawa-Nagata N, Kita Y, Nabemoto S, Akahori H, Zen Y, Nakanuma Y, Kaneko S, Takamura T 2008 Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis. Hepatology 48: 109-118.

• Uraz S, Aygun C, Sonsuz A, Ozbay G 2005 Serum iron levels and hepatic iron overload in nonalcoholic steatohepatitis and chronic viral hepatitis. Dig. Dis. Sci. 50: 964-969. *

• Uribe M, Zamora-Valdes D, Moreno-Portillo M, Bermejo-Martínez L, Pichardo-Bahena R, Baptista-Gonzalez HA, Ponciano-Rodriguez G, Uribe MH, Medina-Santillan R, Mendez-Sanchez N 2008 Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. Ann. Hepatol. 7: 67-71. *

• Uto H, Nakanishi C, Ido A, Hasuike S, Kusumoto K, Abe H, Numata M, Nagata K, Hayashi K, Tsubouchi H 2005 The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, L-amino acid-defined diet. Hepatol. Res. 32: 235-242.

• Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, Deveci MS, Bagci S, Gulsen M, Karaeren N, Dagalp K 2000 Serum leptin levels in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 95: 3584-3589. *

• Valenti L, Dongiovanni P, Piperno A, Fracanzani AL, Maggioni M, Rametta R, Loria P, Casiraghi MA, Suigo E, Ceriani R, Remondini E, Trombini P, Fargion S 2006 alpha1-Antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. Hepatology 44: 857-864. *

• van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, London R, Peduto T, Chisholm DJ, George J 2008 Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 48: 449-457.

• van Hoek B 2004 Non-alcoholic fatty liver disease: a brief review. Scand. J. Gastroenterol. Suppl. 241: 56-59. *

• Varela NM, Quinones LA, Orellana M, Poniachik J, Csendes A, Smok G, Rodrigo R, Caceres DD, Videla LA 2008 Study of cytochrome P450 2E1 and its allele variants in liver injury of nondiabetic, nonalcoholic steatohepatitis obese women. Biol. Res. 41: 81-92. *

• Verdi H, Sare Koytak E, Onder O, Arslan Ergul A, Cinar K, Idilman R, Erden E, Mithat Bozdayi A, Yurdaydin C, Uzunalimoglu O, Bozkaya H 2005 Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis. J. Investig. Med. 53: 353-359.

• Vial P, Riquelme A, Pizarro M, Solis N, Madariaga JA, Aguayo G, Duarte I, Soza A, Accatino L, Arrese M 2006 Pentoxifylline does not prevent neither liver damage nor early profibrogenic events in a rat model of non-alcoholic steatohepatitis. Ann. Hepatol. 5: 25-29. *

• Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quinones L, Varela N, Contreras J, Lazarte R, Csendes A, Rojas J, Maluenda F, Burdiles P, Diaz JC, Smok G, Thielemann L, Poniachik J 2004 Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin. Sci. (Lond.) 106: 261-268. *

• Villeneuve JP, Pichette V 2004 Cytochrome P450 and liver diseases. Curr. Drug Metab. 5: 273-282.

• Vuppalanchi R, Marri S, Kolwankar D, Considine RV, Chalasani N 2005 Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis?: a preliminary human study. J. Clin. Gastroenterol. 39: 237-242.

• Wanless IR, Shiota K 2004 The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin. Liver Dis. 24: 99-106.

• Wei Y, Rector RS, Thyfault JP, Ibdah JA 2008 Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J. Gastroenterol. 14: 193-199. *

• Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE 2008 Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 103: 1372-1379. *

• Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE 2006 In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44: 27-33. *

• Wiesinger HA, Shah J, White A, Yoshida EM, Frohlich J, Sirrs S, Gill S, Byrne MF 2008 Liver biochemistry abnormalities in a quaternary care lipid clinic database. Ann. Hepatol. 7: 63-66. *

• Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG 2001 The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48: 206-211. *

• Wilfred de Alwis NM, Day CP 2007 Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin. Liver Dis. 27: 44-54. *

• Wortham M, He L, Gyamfi M, Copple BL, Wan YJ 2008 The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet. Dig. Dis. Sci. 53: 2761-2774.

• Wu WC, Zhao W, Li S 2008 Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World J. Gastroenterol. 14: 313-317. *

• Xu Z, Chen L, Leung L, Yen TS, Lee C, Chan JY 2005 Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc. Natl. Acad. Sci. U.S.A. 102: 4120-4125. *

• Yakaryilmaz F, Guliter S, Savas B, Erdem O, Ersoy R, Erden E, Akyol G, Bozkaya H, Ozenirler S 2007 Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern. Med. J. 37: 229-235. *

• Yalniz M, Bahcecioglu IH, Kuzu N, Poyrazoglu OK, Bulmus O, Celebi S, Ustundag B, Ozercan IH, Sahin K 2007 Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. J. Gastroenterol. Hepatol. 22: 2009-2014. *

• Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM 2007 Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45: 1366-1374. *

• Yamazaki Y, Kakizaki S, Horiguchi N, Sohara N, Sato K, Takagi H, Mori M, Negishi M 2007 The role of nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis. Gut 56: 565-574. *

• Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, Nakamura K 2004 Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40: 1222-1225. *

• Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y, Kubota K, Saito S, Iwasaki T, Terauchi Y, Togo S, Maeyama S, Nakajima A 2007 High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J. Gastroenterol. 42: 573-582. *

• Yoshioka Y, Hashimoto E, Yatsuji S, Kaneda H, Taniai M, Tokushige K, Shiratori K 2004 Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J. Gastroenterol. 39: 1215-1218. *

• Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, Vanmeter A, Younoszai A, Ong JP, Goodman Z, Chandhoke V 2005 A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 42: 665-674. *

• Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, Rafiq N, Goodman Z, Chandhoke V, Baranova A 2008 A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes. Surg. May 24 [Epub ahead of print].

• Yu AS, Keeffe EB 2002 Nonalcoholic fatty liver disease. Rev. Gastroenterol. Disord. 2: 11-19. *

• Yu J, Ip E, Dela Pena A, Hou JY, Sesha J, Pera N, Hall P, Kirsch R, Leclercq I, Farrell GC 2006 COX-2 induction in mice with experimental nutritional steatohepatitis: role as pro-inflammatory mediator. Hepatology 43: 826-836. *

• Zamora-Valdes D, Mendez-Sanchez N 2007 Experimental evidence of obstructive sleep apnea syndrome as a second hit accomplice in nonalcoholic steatohepatitis pathogenesis. Ann. Hepatol. 6: 281-283. *

• Zatloukal K, Stumptner C, Fuchsbichler A, Fickert P, Lackner C, Trauner M, Denk H 2004 The keratin cytoskeleton in liver diseases. J. Pathol. 204: 367-376. *

• Zetterman RK 2003 Clinical topics in liver disease. American College of Gastroenterology 68th Annual Scientific Meeting and Postgraduate Course, October 10 - 15, 2003, Baltimore, Maryland.

• Zhang SJ, Chen ZX, Jiang KP, Cheng YH, Gu YL 2008 The effect of QuYuHuaTanTongLuo decoction on the non-alcoholic steatohepatitis. Complement. Ther. Med. 16: 192-198.

• Zhou GD, Li MR, Zhang J, Pan D, Zhao SX, Yang JF, Yu J, Zhao JM 2008 Chitosan ameliorates the severity of steatohepatitis induced by high fat diet in rats. Scand. J. Gastroenterol. Jul 25 [Epub ahead of print]. *

Number of references = 456

www psc-literature.org